Asset profile
NRD135S.E1
Small molecule
Evidence outlook · lead readout
NCT05480228 · Painful Diabetic Neuropathy
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05480228: The trial randomized 127 participants to NRD135S.E1 or placebo and used double-blind masking. Its primary pain endpoint was a clinical patient-reported measure, but no results are available to show whether the comparison met its prespecified objective.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.